The contraception needs of the perimenopausal woman

被引:12
作者
Hardman, Sarah M. R. [1 ]
Gebbie, Ailsa E. [1 ]
机构
[1] NHS Lothian Sexual & Reprod Hlth Serv, Chalmers Ctr, Edinburgh EH3 9ES, Midlothian, Scotland
关键词
perimenopause; hormonal contraception; intra-uterine contraception; non-contraceptive benefits; hormone replacement therapy; DEPOT-MEDROXYPROGESTERONE ACETATE; BREAST-CANCER RISK; ORAL-CONTRACEPTIVES; VENOUS THROMBOSIS; HORMONAL CONTRACEPTION; INTRAUTERINE SYSTEM; COLLABORATIVE REANALYSIS; THROMBOEMBOLIC EVENTS; UNINTENDED PREGNANCY; OVARIAN-CANCER;
D O I
10.1016/j.bpobgyn.2014.05.006
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Perimenopausal women have low fertility but must still be advised to use contraception until natural sterility is reached if they are sexually active. Patterns of contraceptive use vary in different countries worldwide. Long-acting reversible contraceptive methods offer reliable contraception that may be an alternative to sterilisation. Hormonal methods confer significant non-contraceptive benefits, and each individual woman should weigh up the benefits and risks of a particular method. No method of contraception is contraindicated by age alone, although combined hormonal contraception and injectable progestogens are not recommended for women over the age of 50 years. The intrauterine system has particular advantages as a low-dose method of effective hormonal contraception, which also offers control of menstrual dysfunction and endometrial protection in women requiring oestrogen replacement Condoms are recommended for personal protection against sexually transmitted infections in new relationships. Standard hormone replacement therapy is not a method of contraception. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:903 / 915
页数:13
相关论文
共 71 条
[1]   LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICE IN THE TREATMENT OF MENORRHAGIA [J].
ANDERSSON, JK ;
RYBO, G .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1990, 97 (08) :690-694
[2]  
[Anonymous], UK MED EL CRIT CONTR
[3]  
[Anonymous], COCHRANE DATABASE SY
[4]  
[Anonymous], 2013, COCHRANE DB SYST REV
[5]  
[Anonymous], CLIN GUID CONTR WOM
[6]  
[Anonymous], COCHRANE DATABASE SY
[7]  
Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5
[8]   Change in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg [J].
Arias, Raquel D. ;
Jain, John K. ;
Brucker, Cosima ;
Ross, Doug ;
Ray, Amrit .
CONTRACEPTION, 2006, 74 (03) :234-238
[9]   Assessing menopausal status in women aged 40-49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception [J].
Beksinska, Mags E. ;
Smit, Jenni A. ;
Kleinschmidt, Immo ;
Farley, Tim M. M. .
SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2011, 101 (02) :131-135
[10]  
Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1